PT  - JOURNAL ARTICLE
AU  - Govathson, Caroline
AU  - Ndlovu, Neo
AU  - Rambally-Greener, Letitia
AU  - Schmucker, Laura
AU  - Chetty-Makkan, Candice
AU  - Miot, Jacqui
AU  - Thirumurthy, Harsha
AU  - Pascoe, Sophie
AU  - Malone, Shawn
AU  - Buttenheim, Alison
TI  - Increasing HIV treatment literacy among people living with HIV using a novel health communication aid: Evidence from KwaZulu Natal province, South Africa
AID  - 10.1101/2023.06.15.23291430
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.15.23291430
4099  - http://medrxiv.org/content/early/2023/08/23/2023.06.15.23291430.short
4100  - http://medrxiv.org/content/early/2023/08/23/2023.06.15.23291430.full
AB  - Introduction Effective health communication is important for promoting adherence to antiretroviral therapy (ART). During counselling sessions with people living with HIV (PLHIV) who are initiating or re-initiating ART, we assessed whether a simple visual aid using bead bottles to explain the concept of viral suppression resulted in changes in HIV treatment literacy.Methods At three public sector clinics in KwaZulu-Natal KZN) province, South Africa, we enrolled adults who tested HIV-positive and were newly initiating ART or re-engaging in HIV care. Trained HIV counsellors used bottles with coloured beads (“B-OK bottles”) to explain concepts related to viral load, viral suppression, and undetectable=Untransmittable (U=U). We assessed participants’ knowledge, attitudes, and perceptions about ART before and after counselling.Results Between November 2022 and January 2023, we enrolled 80 PLHIV. Participants’ median age was 32 years (IQR: 24–41) and 58% were male. After receiving counselling with the B-OK bottles, understanding of U=U increased from 6% to 99% and understanding of ‘viral suppression’ increased from 20% to 99%. Confidence in the protective effects of ART increased (64% to 100% for one’s own health; 58% to 94% for transmission to partners) and was observed among participants both initiating ART and re-engaging in care. The number of participants agreeing that viral suppression means their sexual partners are safe from HIV even without condoms increased from 14% to 93% p-value =0.0. However, 65% still expressed worry that ART does not completely eliminate the risk of sexually transmitting HIV.Conclusions Use of B-OK bottles during ART counselling was acceptable and increased HIV treatment literacy. While there was no significant effect on level of confidence in complete elimination of transmission risk when virally suppressed, we observed a significant reduction in concern about transmitting HIV and an increase in confidence in the protective effects of ART.Clinical Trial Number (SANCTR) DOH-27-092022-8067Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDOH-27-092022-8067Funding StatementThis analysis was funded by the Bill & Melinda Gates Foundation (INV-008318). The contents are the responsibility of the authors and do not necessarily reflect the views of the sponsor. The funders had no role in the study design, collection, analysis and interpretation of the data, in manuscript preparation or the decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committees of University of the Witwatersrand (# M220707) and University of Pennsylvania (# 852087) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes